Zheng Quan Shi Bao Wang·2025-12-02 03:21Core Viewpoint - The retail pharmacy sector has seen a significant surge in stock prices, driven by an increase in flu-like cases and heightened demand for related medications [1] Group 1: Stock Performance - Retail pharmacy stocks collectively rose on the 2nd, with notable gains including a limit-up for Renmin Tongtai and Haiwang Biological, approximately 8% increase for Hefuchina, and over 6% for Yaoyigou [1] - Haiwang Biological has achieved a consecutive five-day limit-up in trading [1] Group 2: Market Drivers - The rapid increase in flu-like cases is expected to benefit the retail pharmacy sector, leading to a surge in demand for antiviral medications such as Oseltamivir [1] - There is a significant rise in the need for symptomatic medications, including antipyretics and cough suppressants, due to the self-medication trend among mild symptom patients [1] - Increased public awareness regarding health protection has led to higher repurchase rates of masks, disinfectants, and hand sanitizers [1]